NKGN — Nkgen Biotech Income Statement
0.000.00%
Last trade - 00:00- $4.60m
- $57.25m
Annual income statement for Nkgen Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0.426 | 0.077 | 0 | 0 |
| Cost of Revenue | ||||
| Gross Profit | 0.396 | 0.059 | 0 | — |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 22.3 | 24.6 | 34.1 | 10.9 |
| Operating Profit | -21.9 | -24.5 | -34.1 | -10.9 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -23.3 | -26.7 | -82.9 | -44.2 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -23.3 | -26.8 | -83 | -44.3 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -23.3 | -26.8 | -83 | -44.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -23.3 | -26.8 | -83 | -44.3 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -1.15 | -1.32 | -3.51 | -1.9 |